HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose more than 6% in the afternoon; the company expects more than 40 marketing applications to be approved in the next two years.

Jiangsu Hengrui Pharmaceuticals (01276) rose more than 6% in the afternoon. As of press time, it was up 6.05% at HK$49.06, with a turnover of HK$315 million. On the news front, the U.S. magazine Pharmaceutical Executive recently released its "2026 Top 50 Global Pharmaceutical Companies" list, and innovation-driven international pharmaceutical company Jiangsu Hengrui Pharmaceuticals was included again. Since 2019, the company has made the list for eight consecutive years. PharmExec is a well-known pharmaceutical professional magazine in the international pharmaceutical industry, and this year marks its 26th release of the Top 50 Global Pharmaceutical Companies list. It is worth noting that Jiangsu Hengrui Pharmaceuticals said on September 10 at its 2026 interim results briefing that it expects more than 40 marketing applications to be approved during 2027-2028, covering five major therapeutic areas, among which potential blockbuster products include SHR-A2009, the first domestically filed single-target HER3 ADC drug, among others.